#USA #New York #Hoth Therapeutics #HT-001 #EGFR inhibitors

Hoth Therapeutics Reports Positive Initial Data in Phase 2a Clinical Trial

Hoth Therapeutics, Inc., a biopharmaceutical company dedicated to innovative therapies for patients, has announced promising interim results from the open-label segment of its Phase 2a clinical trial known as CLEER-001. This study evaluates HT-001, a proprietary topical treatment designed for pruritus linked to skin toxicities caused by Epidermal Growth Factor Receptor (EGFR) inhibitors, commonly used in cancer therapies.

EGFR inhibitors, while effective in treating cancer, often lead to bothersome skin-related side effects, particularly intense itching or pruritus. Such side effects can significantly diminish a patient’s quality of life and adherence to treatment regimens. Recognizing this critical issue, Hoth Therapeutics developed HT-001 to offer targeted relief without the systemic side effects that often accompany traditional treatments.

Key Findings from the Trial

The interim data showcase a 50% reduction in pruritus severity among patients treated with HT-001, as measured by a mean score decline from 1.6 on Day 1 to 0.8 by Day 21. Notably, rapid symptom relief was observed, with scores improving to 1.0 by Day 7 of treatment. Additionally, some patients reported complete resolution of pruritus during the 21-day assessment period. Importantly, HT-001 was well tolerated, with no serious adverse events related to the treatment reported during the study.

Robb Knie, Chief Executive Officer of Hoth Therapeutics, emphasized the significance of these results: *"These findings support the potential of HT-001 to deliver meaningful relief for cancer patients experiencing EGFR-related pruritus. Cutaneous toxicities can significantly impact quality of life and may interfere with treatment. Our goal is to provide a safe and effective therapy that enhances patient comfort and continuity of care."

The study, CLEER-001, continues as both the open-label and randomized, double-blind segments are ongoing, providing further insights into the potential benefits of HT-001 in alleviating pruritus associated with cancer treatment.

About HT-001

HT-001 is a unique, non-steroidal topical formulation specifically designed to treat pruritus and other inflammatory skin conditions associated with targeted cancer treatments. By focusing on localized application, HT-001 aims to alleviate itching and irritation while minimizing the risk of systemic side effects, thereby promoting a better treatment experience for cancer patients.

Hoth Therapeutics Overview

Hoth Therapeutics is at the forefront of clinical-stage biopharmaceutical innovation. The company is committed to developing impactful therapies that address significant unmet medical needs, enhancing the overall quality of life for patients. Hoth Therapeutics utilizes a patient-centric model, collaborating with a diverse team of scientists, clinicians, and key opinion leaders to bring promising therapeutic solutions to the forefront of patient care.

As Hoth Therapeutics moves forward with its clinical trials and innovative research, it aims to redefine the therapeutic landscape for patients facing challenging skin conditions due to cancer treatments. The latest results from the CLEER-001 trial embody their mission to advance patient care and improve quality of life for those dealing with the complexities of cancer treatment and its side effects.

For more information about Hoth Therapeutics and its ongoing projects, including updates on HT-001, visit their official website.